Clinical Trial Update: Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women [Phase 3]

View source ↗

Summary

Phase 3 trial comparing E/C/F/TDF with RTV-boosted ATV plus FTC/TDF in ART-naive women with HIV-1, assessing safety and efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Immunodeficiency Syndrome
• HIV Infections

Drugs mentioned

• emtricitabine/tenofovir disoproxil fumarate/elvitegravir/cobicistat (emtricitabine/tenofovir disoproxil fumarate/elvitegravir/cobicistat)
• ritonavir-boosted atazanavir plus emtricitabine/tenofovir disoproxil fumarate (atazanavir/ritonavir + emtricitabine/tenofovir disoproxil fumarate)

Snippet

Sponsor: Gilead Sciences | Conditions: Acquired Immunodeficiency Syndrome, HIV Infections | Phase 3 | Status: COMPLETED | Results posted: 2016-03-10